Carcinoma of unknown primary site: Development in a single institution of a prognostic model based on clinical and serum variables

Clinical and Translational Oncology

Volumn 9, Issue 7, 2007, Pages 452-458

  Lorenzo Ponce, Jose ^a   Segura Huerta, A ^a   Diaz Beveridge R ^a   Gimenez Ortiz A ^a   Aparisi Aparisi, F ^a   Fleitas Kanonnikoff, T ^a   Richart Aznar, P ^a   de la Cueva Sapina H ^a   Montalar Salcedo, J ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Cancer of unknown primary site; Chemotherapy; Prognostic factors; Treatment

Indexed keywords

ALKALINE PHOSPHATASE; CARBOPLATIN; DOCETAXEL; GEMCITABINE; LACTATE DEHYDROGENASE; PACLITAXEL; PLATINUM COMPLEX; SERUM ALBUMIN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER LOCALIZATION; CANCER OF UNKNOWN PRIMARY SITE; CANCER RADIOTHERAPY; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHYSICAL PERFORMANCE; PLEURA METASTASIS; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL MODEL; SURVIVAL TIME; TUMOR BIOPSY; WEIGHT REDUCTION; BIOLOGICAL MODEL; BLOOD; CARCINOMA; METABOLISM; METASTASIS; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASM; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; HUMANS; MALE; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; NEOPLASMS, UNKNOWN PRIMARY; PROGNOSIS; RETROSPECTIVE STUDIES; SERUM ALBUMIN; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 35748972072     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0084-6     Document Type: Article

References (28)

1. Muir C (1995) Cancer of unknown primary site. Cancer 75:353
2. Pavlidis N, Briasoulis E, Hainsworth J et al (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39:1990
3. Hainsworth JD, Greco FA (1993) Treatment of patients with cancer of an unknown primary site. N Engl J Med 329:257-263
4. Sporn JR, Greenberg BR (1993) Empirical chemotherapy for adenocarcinoma of unknown primary site. Semin Oncol 20:261-267
5. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
6. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-167
7. Daugaard G (1994) Unknown primary tumours. Cancer Treat Rev 20:119-147
8. Kambhu SA, Kelsen DP, Fiore J et al (1990) Metastatic adenocarcinomas of unknown primary site: Prognostic variables and treatment results. Am J Clin Oncol 13:55-60
9. Hainsworth JD, Johnson DH, Greco FA (1992) Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: Results of a 12-year experience. J Clin Oncol 10:912-922
10. Abbruzzese JL, Abbruzzese MC, Hess KR et al (1994) Unknown primary carcinoma: Natural history and prognostic factors in 657 patients. J Clin Oncol 12:1272-1280
11. Van der Gaast A, Verweij J, Planting AST et al (1995) Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. J Clin Oncol 13:1720-1725
12. Culine S, Kramar A, Saghatchian M et al (2002) Development of a prognostic model to predict the length of survival inpatients with carcinomas of an unknown primary site. J Clin Oncol 20:4679-4683
13. Hess KR, Abbruzzese MC, Lenzi R et al (1999) Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 5:3403-3410
14. Culine S, Fabbro M, Ychou Y et al (1999) Chemotherapy in carcinomas of unknown primary site: A high-dose intensity police. Ann Oncol 10:569-575
15. Culine S, Fabbro M, Ychou Y et al (2002) Alternatively bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site. Cancer 94:840-846
16. Saghatchian M, Fizazi K, Borel C et al (2001) carcinoma of unknown primary site: A chemotherapy strategy based on histological differentiation - results of a prospective study. Ann Oncol 12:535-540
17. Lortholary A, Culine S, Bouzy J et al (2002) Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of an unknown primary (CUP): Results of a randomized phase II study. Proc Am Soc Clin Oncol 21:153a (abstr 609)
18. Palmeri S, Lorusso V, Palmeri L et al; Carcinomas of Unknown Primary Italian Study Group (2006) Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site: Results of an Italian multicenter, randomized, phase II study. Cancer 107:2898-2905
19. Hainsworth JD, Spigel DR, Litchy S, Greco FA (2006) Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: A Minnie Pearl Cancer Research Network Study. J Clin Oncol 24:3548-3554
20. El-Rayes BF, Shields AF, Zalupski M et al (2005) A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary. Am J Clin Oncol 28:152-156
21. Greco FA, Erland JB, Morrissey LH et al (2000) Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 11:211-215
22. Rebattu P, Quantin X, Ardiet C et al (2001) Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Lung Cancer 33:277-287
23. Stathopoulus GP, Mavroudis D, Tsavaris N et al (2001) Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for pancreatic cancer. Ann Oncol 12:101-103
24. Alberts SR, Townley PM, Goldberg RM et al (2002) Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group Phase I Study. Ann Oncol 13:553-557
25. Faivre S, Le Chevalier T, Monnerat C et al (2002) Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol 13:1479-1489
26. André T, Tournigand C, Rosmordue O et al (2004) Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma (ABTA): A GERCOR study. Ann Oncol 15:1339-1343
27. Motzer RJ, Rodriguez E, Reuter VE et al (1995) Molecular and cytogenic studies in the diagnosis of patients with midline carcinomas of unknown primary site. J Clin Oncol 13:274
28. Ramaswamy S, Golub TR (2002) DNA microarrays in clinical oncology. J Clin Oncol 20:1932